Compare Medpace Holdings Inc (MEDP) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs NRG Energy Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while NRG Energy Inc trades at $107.97 (market cap $22.35B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and NRG Energy Inc for 63 Days on average.
| MEDP | NRG | |
|---|---|---|
Market Cap | $16.82B | $22.35B |
Volume | 223,093 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $630.19 | $184.03 |
52-Week Low | $393.42 | $95.23 |
Typical Hold Time | 14 Days | 63 Days |
Enterprise Value | $16.44B | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
NRG Energy trades at $106.32, down 2.11% today, with a bullish technical signal and strong analyst support. The stock shows mixed earnings performance with recent misses but maintains solid fundamentals including $30.71B revenue and 2.56% net margin. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant, positioning for growth in energy infrastructure.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus price target representing 91% upside. Key risks include execution of major capital projects, debt levels at 56.42% of assets, and energy market volatility. The dividend yield of approximately 1.6% provides income support while growth initiatives drive long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
